Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIND Biosciences Inc.

This article was originally published in Start Up

Executive Summary

BIND Biosciences generates nanoparticles with unique targeting agents that allow them to home in on cancerous cells with deadly precision. Because it's impossible to mathematically design the optimal particle, BIND scientists have created large combinatorial libraries of nanoparticles with different biophysical and chemical properties.
Advertisement

Related Content

In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
FDA Seeks Public Input To Develop Guidance For Nanotechnology In Pharmaceuticals
Tempo Pharmaceuticals Inc.
TransGenex Nanobiotech Inc.
Liquidia Technologies Inc.
Nanolymf Ltd.
Start-Up Previews (04/2008)
Nanotechnology: A Balm for the Challenges of Drug Delivery
Nanotechnology: A Balm for the Challenges of Drug Delivery
Start-Up Previews (04/2008)

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091562

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel